Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;37(1):21-30.
doi: 10.1002/cbf.3369. Epub 2019 Jan 2.

The PROTAC technology in drug development

Yutian Zou  1   2 , Danhui Ma  1 , Yinyin Wang  1
Affiliations
Review

The PROTAC technology in drug development

Yutian Zou et al. Cell Biochem Funct. 2019 Jan.

Abstract

Currently, a new technology termed PROTAC, proteolysis targeting chimera, has been developed for inducing the protein degradation by a targeting molecule. This technology takes advantage of a moiety of targeted protein and a moiety of recognizing E3 ubiquitin ligase and produces a hybrid molecule to specifically knock down a targeted protein. During the first decade, three pedigreed groups worked on the development of this technology. To date, this technology has been extended by different groups, aiming to develop new drugs against different diseases including cancers. This review summarizes the contributions of the groups for the development of PROTAC. SIGNIFICANCE OF THE STUDY: This review summarized the development of the PROTAC technology for readers and also presented the author's opinions on the application of the technology in tumor therapy.

Keywords: PROTAC; cancer; drug development; protein degradation; small molecule.

PubMed Disclaimer

Conflict of interest statement

There are no other conflicts of interest to disclose.

Figures

Figure 1
Figure 1
A graph view of the publications on the proteolysis targeting chimera (PROTAC) technology. Research articles and reviews on PROTAC were searched from Pubmed (https://www.ncbi.nlm.nih.gov/pubmed). The literatures were presented chronologically from 2011. Numbers up columns indicate the total number of article and review papers
Figure 2
Figure 2
A diagram to demonstrate the proteolysis targeting chimera (PROTAC) molecule designs. Only effective PROTACs are presented. Targeted protein is labelled in red colour, and the recruited E3 ubiquitin ligase is labelled in blue colour. A box indicate a research group. Abbreviations of the ligands are listed
Figure 3
Figure 3
A schematic diagram of a peptide‐based proteolysis targeting chimera (PROTAC). This PROTAC is composed of a short peptide that binds to E3 ubiquitin ligase and a small molecular that binds to target protein, respectively, followed by polyubiquitination and proteasome degradation of target
Figure 4
Figure 4
A schematic diagram of the small molecule‐based PROTACs. This proteolysis targeting chimera (PROTAC) consists of a ligand on an E3 ubiquitin ligase, a linker, and a ligand on targeted protein
Figure 5
Figure 5
A summary of targeted proteins, ligands for target, ligand for E3 ubiquitin ligases, and recruited E3 ubiquitin ligases. MetAP‐2, methionine aminopeptidase‐2; ER, estrogen receptor; AR, androgen receptor; HTT, huntingtin protein; ERRα, estrogen‐related receptor alpha; AHR, activation of the aryl hydrocarbon receptor; CRABP‐I/II, cellular retinoic acid binding protein‐I/II; BRD4, bromodomain‐containing protein 4; TACC3, transforming acidic coiled‐coil‐3, spindle‐regulatory protein; DHODH, dihydroorotate dehydrogenase; DAPK, death‐associated protein kinase 1; PSD‐95, postsynaptic density protein 95; ALK, anaplastic lymphoma kinase; TBK1, TANK‐binding kinase 1; RIPK2, receptor‐interacting protein kinase 2; c‐Abl, Abelson nonreceptor tyrosine kinase; VHL, von‐Hippel‐Lindau ubiquitin ligase; CMA, chaperon‐meditated autophage; SCFb‐TRCP, Skip‐Cullin‐F box (β‐TRCP) ubiquitin complex; b‐TRCP, b‐transducing repeat‐containing protein; cIAP1, cellular inhibitor of apoptosis protein 1; MDM2, mouse double minute 2 homologue; APC/C, anaphase‐promoting complex/cyclosome
See this image and copyright information in PMC

References

    1. Lu J, Qian Y, Altieri M, et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol. 2015;22(6):755‐763. - PMC - PubMed
    1. Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1‐Cullin‐F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S a. 2001;98(15):8554‐8559. - PMC - PubMed
    1. Mansour MA. Ubiquitination: friend and foe in cancer. Int J Biochem Cell Biol. 2018;101:80‐93. - PubMed
    1. Zhou P, Bogacki R, McReynolds L, Howley PM. Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol Cell. 2000;6(3):751‐756. - PubMed
    1. Sakamoto KM. Chimeric molecules to target proteins for ubiquitination and degradation. Methods Enzymol. 2005;399:833‐847. - PubMed

MeSH terms

Substances